Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

The expression of TGF-β1, Smad3, phospho-Smad3 and Smad7 is correlated with the development and invasion of nonfunctioning pituitary adenomas

Authors: Li Zhenye, Li Chuzhong, Wu Youtu, Lan Xiaolei, Cao Lei, Hong Lichuan, Wang Hongyun, Wu Yonggang, Wang Fei, Zhang Yazhuo

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

Transforming growth factor β (TGF-β) signaling functions as a suppressor or a promoter in tumor development, depending on the tumor stage and type. However, the role of TGF-β signaling in nonfunctioning pituitary adenomas (NFPAs) has not been explored.

Methods

TGF-β1, Smad2, phospho-Smad2 (p-Smad2), Smad3, phospho-Smad3 (p-Smad3), Smad4, and Smad7 were detected in 5 cases of normal anterior pituitaries, 29 cases of invasive NFPAs, and 21 cases of noninvasive NFPAs by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemical analysis.

Results

The Smad3 and p-Smad3 protein levels gradually decreased from normal anterior pituitaries, noninvasive NFPAs, to invasive NFPAs. However, there were no significant differences in Smad2 (P = 0.122) and p-Smad2 protein levels (P = 0.101) or Smad2 mRNA level (P = 0.409). In addition, the TGF-β1 mRNA level gradually decreased while the Smad7 mRNA level gradually increased from normal anterior pituitaries, noninvasive NFPAs, to invasive NFPAs. Furthermore, proliferating cell nuclear antigen (PCNA) mRNA level was markedly increased in invasive NFPAs compared to noninvasive ones (P < 0.01), and its level was negatively correlated with Smad3 mRNA level (P < 0.01).

Conclusion

The activity of TGF-β signaling may be restrained in NFPAs and is correlated with the development and invasion of NFPAs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006, 91: 4769-4775. 10.1210/jc.2006-1668.CrossRefPubMed Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006, 91: 4769-4775. 10.1210/jc.2006-1668.CrossRefPubMed
2.
go back to reference Fernandez A, Karavitaki N, Wass JA: Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010, 72: 377-382. 10.1111/j.1365-2265.2009.03667.x.CrossRef Fernandez A, Karavitaki N, Wass JA: Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010, 72: 377-382. 10.1111/j.1365-2265.2009.03667.x.CrossRef
3.
go back to reference Figarella-Branger D, Trouillas J: The new WHO classification of human pituitary tumors: comments. Acta Neuropathol. 2006, 111: 71-72. 10.1007/s00401-005-1099-0.CrossRefPubMed Figarella-Branger D, Trouillas J: The new WHO classification of human pituitary tumors: comments. Acta Neuropathol. 2006, 111: 71-72. 10.1007/s00401-005-1099-0.CrossRefPubMed
4.
go back to reference Buchfelder M: Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 2009, 12: 256-260. 10.1007/s11102-008-0153-z.CrossRefPubMed Buchfelder M: Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 2009, 12: 256-260. 10.1007/s11102-008-0153-z.CrossRefPubMed
5.
go back to reference Katznelson L, Alexander JM, Klibanski A: Clinical review 45: clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 1993, 76: 1089-1094.PubMed Katznelson L, Alexander JM, Klibanski A: Clinical review 45: clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 1993, 76: 1089-1094.PubMed
6.
go back to reference Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S: Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 2008, 15: 905-915. 10.1677/ERC-08-0181.CrossRefPubMed Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S: Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 2008, 15: 905-915. 10.1677/ERC-08-0181.CrossRefPubMed
7.
go back to reference Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S: Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990, 71: 1427-1433. 10.1210/jcem-71-6-1427.CrossRefPubMed Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S: Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990, 71: 1427-1433. 10.1210/jcem-71-6-1427.CrossRefPubMed
8.
go back to reference Gurlek A, Karavitaki N, Ansorge O, Wass JA: What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol. 2007, 156: 143-153. 10.1530/eje.1.02339.CrossRefPubMed Gurlek A, Karavitaki N, Ansorge O, Wass JA: What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol. 2007, 156: 143-153. 10.1530/eje.1.02339.CrossRefPubMed
9.
go back to reference Melmed S: Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011, 7: 257-266. 10.1038/nrendo.2011.40.CrossRefPubMed Melmed S: Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011, 7: 257-266. 10.1038/nrendo.2011.40.CrossRefPubMed
10.
go back to reference Wakefield LM, Roberts AB: TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002, 12: 22-29. 10.1016/S0959-437X(01)00259-3.CrossRefPubMed Wakefield LM, Roberts AB: TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002, 12: 22-29. 10.1016/S0959-437X(01)00259-3.CrossRefPubMed
12.
go back to reference Heldin CH, Miyazono K, ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997, 390: 465-471. 10.1038/37284.CrossRefPubMed Heldin CH, Miyazono K, ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997, 390: 465-471. 10.1038/37284.CrossRefPubMed
13.
go back to reference Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P: Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature. 1997, 389: 631-635. 10.1038/39369.CrossRefPubMed Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P: Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature. 1997, 389: 631-635. 10.1038/39369.CrossRefPubMed
15.
go back to reference Wu Y, Li Q, Zhou X, Yu J, Mu Y, Munker S, Xu C, Shen Z, Mullenbach R, Liu Y, Li L, Gretz N, Zieker D, Weng H: Decreased levels of active SMAD2 correlate with poor prognosis in gastric cancer. PLoS One. 2012, 7: e35684-10.1371/journal.pone.0035684.PubMedCentralCrossRefPubMed Wu Y, Li Q, Zhou X, Yu J, Mu Y, Munker S, Xu C, Shen Z, Mullenbach R, Liu Y, Li L, Gretz N, Zieker D, Weng H: Decreased levels of active SMAD2 correlate with poor prognosis in gastric cancer. PLoS One. 2012, 7: e35684-10.1371/journal.pone.0035684.PubMedCentralCrossRefPubMed
16.
go back to reference Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007, 11: 147-160. 10.1016/j.ccr.2006.11.023.CrossRefPubMed Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007, 11: 147-160. 10.1016/j.ccr.2006.11.023.CrossRefPubMed
17.
go back to reference Johnson MD, Shaw AK, O'Connell MJ, Sim FJ, Moses HL: Analysis of transforming growth factor beta receptor expression and signaling in higher grade meningiomas. J Neurooncol. 2011, 103: 277-285. 10.1007/s11060-010-0399-y.CrossRefPubMed Johnson MD, Shaw AK, O'Connell MJ, Sim FJ, Moses HL: Analysis of transforming growth factor beta receptor expression and signaling in higher grade meningiomas. J Neurooncol. 2011, 103: 277-285. 10.1007/s11060-010-0399-y.CrossRefPubMed
18.
go back to reference de Kruijf EM, Dekker TJ, Hawinkels LJ, Putter H, Smit VT, Kroep JR, Kuppen PJ, van de Velde CJ, ten Dijke P, Tollenaar RA, Mesker WE: The prognostic role of TGF-beta signaling pathway in breast cancer patients. Ann Oncol. 2013, 24: 384-390. 10.1093/annonc/mds333.CrossRefPubMed de Kruijf EM, Dekker TJ, Hawinkels LJ, Putter H, Smit VT, Kroep JR, Kuppen PJ, van de Velde CJ, ten Dijke P, Tollenaar RA, Mesker WE: The prognostic role of TGF-beta signaling pathway in breast cancer patients. Ann Oncol. 2013, 24: 384-390. 10.1093/annonc/mds333.CrossRefPubMed
19.
go back to reference Wilson CB: A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg. 1984, 61: 814-833. 10.3171/jns.1984.61.5.0814.CrossRefPubMed Wilson CB: A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg. 1984, 61: 814-833. 10.3171/jns.1984.61.5.0814.CrossRefPubMed
20.
go back to reference Knosp E, Steiner E, Kitz K, Matula C: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993, 33: 610-617. 10.1227/00006123-199310000-00008. discussion 617–618CrossRefPubMed Knosp E, Steiner E, Kitz K, Matula C: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993, 33: 610-617. 10.1227/00006123-199310000-00008. discussion 617–618CrossRefPubMed
21.
go back to reference Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed
22.
go back to reference Zhou W, Song Y, Xu H, Zhou K, Zhang W, Chen J, Qin M, Yi H, Gustafsson JA, Yang H, Fan X: In nonfunctional pituitary adenomas, estrogen receptors and slug contribute to development of invasiveness. J Clin Endocrinol Metab. 2011, 96: E1237-E1245. 10.1210/jc.2010-3040.CrossRefPubMed Zhou W, Song Y, Xu H, Zhou K, Zhang W, Chen J, Qin M, Yi H, Gustafsson JA, Yang H, Fan X: In nonfunctional pituitary adenomas, estrogen receptors and slug contribute to development of invasiveness. J Clin Endocrinol Metab. 2011, 96: E1237-E1245. 10.1210/jc.2010-3040.CrossRefPubMed
23.
go back to reference ten Dijke P, Hill CS: New insights into TGF-beta-Smad signalling. Trends Biochem Sci. 2004, 29: 265-273. 10.1016/j.tibs.2004.03.008.CrossRefPubMed ten Dijke P, Hill CS: New insights into TGF-beta-Smad signalling. Trends Biochem Sci. 2004, 29: 265-273. 10.1016/j.tibs.2004.03.008.CrossRefPubMed
24.
go back to reference Ten Dijke P, Goumans MJ, Itoh F, Itoh S: Regulation of cell proliferation by Smad proteins. J Cell Physiol. 2002, 191: 1-16. 10.1002/jcp.10066.CrossRefPubMed Ten Dijke P, Goumans MJ, Itoh F, Itoh S: Regulation of cell proliferation by Smad proteins. J Cell Physiol. 2002, 191: 1-16. 10.1002/jcp.10066.CrossRefPubMed
25.
go back to reference Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006, 24: 99-146. 10.1146/annurev.immunol.24.021605.090737.CrossRefPubMed Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006, 24: 99-146. 10.1146/annurev.immunol.24.021605.090737.CrossRefPubMed
26.
go back to reference Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE, Byfield S, Felici A, Flanders KC, Walz TM, Roberts AB, Aplan PD, Balis FM, Letterio JJ: Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med. 2004, 351: 552-559. 10.1056/NEJMoa031197.CrossRefPubMed Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE, Byfield S, Felici A, Flanders KC, Walz TM, Roberts AB, Aplan PD, Balis FM, Letterio JJ: Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med. 2004, 351: 552-559. 10.1056/NEJMoa031197.CrossRefPubMed
27.
go back to reference Sodir NM, Chen X, Park R, Nickel AE, Conti PS, Moats R, Bading JR, Shibata D, Laird PW: Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res. 2006, 66: 8430-8438. 10.1158/0008-5472.CAN-06-1437.CrossRefPubMed Sodir NM, Chen X, Park R, Nickel AE, Conti PS, Moats R, Bading JR, Shibata D, Laird PW: Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res. 2006, 66: 8430-8438. 10.1158/0008-5472.CAN-06-1437.CrossRefPubMed
28.
go back to reference Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M: The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene. 1999, 18: 5363-5372. 10.1038/sj.onc.1202909.CrossRefPubMed Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M: The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene. 1999, 18: 5363-5372. 10.1038/sj.onc.1202909.CrossRefPubMed
29.
go back to reference Halder SK, Rachakonda G, Deane NG, Datta PK: Smad7 induces hepatic metastasis in colorectal cancer. Br J Cancer. 2008, 99: 957-965. 10.1038/sj.bjc.6604562.PubMedCentralCrossRefPubMed Halder SK, Rachakonda G, Deane NG, Datta PK: Smad7 induces hepatic metastasis in colorectal cancer. Br J Cancer. 2008, 99: 957-965. 10.1038/sj.bjc.6604562.PubMedCentralCrossRefPubMed
30.
go back to reference Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996, 271: 350-353. 10.1126/science.271.5247.350.CrossRefPubMed Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996, 271: 350-353. 10.1126/science.271.5247.350.CrossRefPubMed
31.
go back to reference Wang LH, Kim SH, Lee JH, Choi YL, Kim YC, Park TS, Hong YC, Wu CF, Shin YK: Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res. 2007, 13: 102-110. 10.1158/1078-0432.CCR-06-1467.CrossRefPubMed Wang LH, Kim SH, Lee JH, Choi YL, Kim YC, Park TS, Hong YC, Wu CF, Shin YK: Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res. 2007, 13: 102-110. 10.1158/1078-0432.CCR-06-1467.CrossRefPubMed
32.
go back to reference Natsugoe S, Xiangming C, Matsumoto M, Okumura H, Nakashima S, Sakita H, Ishigami S, Baba M, Takao S, Aikou T: Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res. 2002, 8: 1838-1842.PubMed Natsugoe S, Xiangming C, Matsumoto M, Okumura H, Nakashima S, Sakita H, Ishigami S, Baba M, Takao S, Aikou T: Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res. 2002, 8: 1838-1842.PubMed
33.
go back to reference Bierie B, Moses HL: TGF-beta and cancer. Cytokine Growth Factor Rev. 2006, 17: 29-40. 10.1016/j.cytogfr.2005.09.006.CrossRefPubMed Bierie B, Moses HL: TGF-beta and cancer. Cytokine Growth Factor Rev. 2006, 17: 29-40. 10.1016/j.cytogfr.2005.09.006.CrossRefPubMed
34.
go back to reference Recouvreux MV, Camilletti MA, Rifkin DB, Becu-Villalobos D, Diaz-Torga G: Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-beta1 (TGF-beta1). Endocrinology. 2012, 153: 3861-3871. 10.1210/en.2012-1007.PubMedCentralCrossRefPubMed Recouvreux MV, Camilletti MA, Rifkin DB, Becu-Villalobos D, Diaz-Torga G: Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-beta1 (TGF-beta1). Endocrinology. 2012, 153: 3861-3871. 10.1210/en.2012-1007.PubMedCentralCrossRefPubMed
35.
go back to reference Bravo R, Frank R, Blundell PA, Macdonald-Bravo H: Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987, 326: 515-517. 10.1038/326515a0.CrossRefPubMed Bravo R, Frank R, Blundell PA, Macdonald-Bravo H: Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987, 326: 515-517. 10.1038/326515a0.CrossRefPubMed
36.
go back to reference Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A, Hedley-Whyte ET: Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg. 1993, 78: 753-761. 10.3171/jns.1993.78.5.0753.CrossRefPubMed Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A, Hedley-Whyte ET: Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg. 1993, 78: 753-761. 10.3171/jns.1993.78.5.0753.CrossRefPubMed
37.
go back to reference Recouvreux MV, Guida MC, Rifkin DB, Becu-Villalobos D, Diaz-Torga G: Active and total transforming growth factor-beta1 are differentially regulated by dopamine and estradiol in the pituitary. Endocrinology. 2011, 152: 2722-2730. 10.1210/en.2010-1464.PubMedCentralCrossRefPubMed Recouvreux MV, Guida MC, Rifkin DB, Becu-Villalobos D, Diaz-Torga G: Active and total transforming growth factor-beta1 are differentially regulated by dopamine and estradiol in the pituitary. Endocrinology. 2011, 152: 2722-2730. 10.1210/en.2010-1464.PubMedCentralCrossRefPubMed
Metadata
Title
The expression of TGF-β1, Smad3, phospho-Smad3 and Smad7 is correlated with the development and invasion of nonfunctioning pituitary adenomas
Authors
Li Zhenye
Li Chuzhong
Wu Youtu
Lan Xiaolei
Cao Lei
Hong Lichuan
Wang Hongyun
Wu Yonggang
Wang Fei
Zhang Yazhuo
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-71

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.